Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the North West of Pakistan

Burns

Volumn 35, Issue 7, 2009, Pages 1020-1025

  Ullah, Farhat ^a,b   Malik, Salman Akbar ^a   Ahmed, Jawad ^b  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b KHYBER TEACHING HOSPITAL   (Pakistan)

Author keywords

Antimicrobial susceptibility; Burns; Extended Spectrum Beta Lactamases; Pseudomonas infections

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFACLOR; CEFPIROME; CEFRADINE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ENOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BURN; CHILD; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PAKISTAN; PRESCHOOL CHILD; PREVALENCE; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BETA-LACTAMASES; BURNS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; WOUND INFECTION;

EID: 70349105031     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2009.01.005     Document Type: Article

References (59)

1. Atlas R.M. Microbiology, Fundamentals and Applications (1984), Macmillan, New York
2. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 51 (2003) 347-352
3. Altoparlak U., Erol S., Akcay M.N., Celebi F., and Kadanali A. The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 30 (2004) 660-664
4. Bloemsma G.C., Dokter J., Boxma H., and Oen I.M. Mortality and causes of death in a burn centre. Burns 34 (2008) 1103-1107
5. Rastegar Lari A., Bahrami Honar H., and Alaghehbandan R. Pseudomonas infections in Tohid Burn Center, Iran. Burns 24 (1998) 637-641
6. Revathi G., Puri J., and Jain B.K. Bacteriology of burns. Burns 24 (1998) 347-349
7. Komolafe O.O., James J., Kalongolera L., and Makoka M. Bacteriology of burns at the Queen Elizabeth Central Hospital, Blantyre, Malawi. Burns 29 (2003) 235-238
8. Tredget E.E., Shankowsky H.A., Rennie R., Burrell R.E., and Logsetty S. Pseudomonas infections in the thermally injured patient. Burns 30 (2004) 3-26
9. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., and Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50 (2006) 43-48
10. Armour A.D., Shankowsky H.A., Swanson T., Lee J., and Tredget E.E. The impact of nosocomially-acquired resistant Pseudomonas aeruginosa infection in a burn unit. J Trauma 63 (2007) 164-171
11. Hancock R.E.W. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 27 (1998) S93-S99
12. Mesaros N., Nordmann P., Plesiat P., Roussell-Delvallez M., Van Eldere J., Glupczynski Y., et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13 (2007) 560-578
13. Paterson D.L., and Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18 (2005) 657-686
14. Philippon A., Labia R., and Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother 33 (1989) 1131-1136
15. Lucet J.C., Decre D., Fichelle A., Joly-Guillou M.L., Pernet M., Deblangy C., et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 29 (1999) 1411-1418
16. Pena C., Pujol M., Ardanuy C., Ricart A., Pallares R., Liñares J., et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 42 (1998) 53-58
17. Quale J.M., Landman D., Bradford P.A., et al. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 35 (2002) 834-841
18. Meyer K.S., Urban C., Eagan J.A., Berger B.J., and Rahal J.J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 119 (1993) 353-358
19. Mathur P., Kapil A., Das B., and Dhawan B. Prevalence of extended spectrum beta lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 115 (2002) 153-157
20. Ali A.M., Rafi S., and Hussain Z. ESBL producing Nosocomial Enterobacteria isolated from clinical specimens detected by Double Disc Diffusion Method. Infect Dis J 12 (2003) 101-106
21. Singh N.P., Goyal R., Manchanda V., Das S., Kaur I., and Talwar V. Changing trends in bacteriology of burns in the burns unit, Delhi, India. Burns 29 (2003) 129-132
22. Japoni A., Alborzi A., Kalani M., Nasiri J., Hayati M., and Farshad S. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 32 (2006) 343-347
23. Walkty A., Decorby M., Nichol K., Mulvey M.R., Hoban D., and Zhanel G. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn Microbiol Infect Dis 61 (2008) 217-221
24. Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., and Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States 1998 to 2001. Antimicrob Agents Chemother 47 (2003) 1681-1688
25. Gad G.F., el-Domany R.A., and Ashour H.M. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt. J Urol 180 (2008) 176-181
26. Shahid M., and Malik A. Resistance due to aminoglycoside modifying enzymes in Pseudomonas aeruginosa isolates from burns patients. Indian J Med Res 122 (2005) 324-329
27. Jung R., Fish D.N., Obritsch M.D., and MacLaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 57 (2004) 105-111
28. Oie S., Sawa A., Kamiya A., and Mizuno H. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 44 (1999) 689-691
29. Babini G.S., and Livermore D.M. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 45 (2000) 183-189
30. Agnihotri N., Gupta V., and Joshi R.M. Aerobic bacterial isolates from burn wound infections and their antibiograms-a five-year study. Burns 30 (2004) 241-243
31. Kaushik R., Kumar S., Sharma R., and Lal P. Bacteriology of burn wounds-the first three years in a new burn unit at the Medical College Chandigarh. Burns 27 (2001) 595-597
32. Suginaka H., Ichikawa A., and Kotani S. Penicillin-resistant mechanisms in Pseudomonas aeruginosa, binding of penicillin to Pseudomonas aeruginosa KM 338. Antimicrob Agents Chemother 7 (1975) 629-635
33. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare?. Clin Infect Dis 34 (2002) 634-640
34. Nicolau D.P. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9 (2008) 23-37
35. Shah P.M. Parenteral carbapenems. Clin Microbiol Infect 14 Suppl. 1 (2008) 175-180
36. Al-Jasser A.M., and Elkhizzi N.A. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa. Saudi Med J 25 (2004) 780-784
37. Ramakrishnan M.K., Sankar J., Venkatraman J., and Ramesh J. Infections in burn patients-experience in a tertiary care hospital. Burns 32 (2006) 594-596
38. Trevor A.J., Katzung B.G., and Masters S.B. Katzungs Pharmacology: Examination and Board Review (2001), McGraw-Hill/Appleton & Lange, New York
39. Astal Z. Susceptibility patterns in Pseudomonas aeruginosa causing nosocomial infections. J Chemother 16 (2004) 264-268
40. Khan J.A., Iqbal Z., Rahman S.U., Farzana K., and Khan A. Report: prevalence and resistance pattern of Pseudomonas aeruginosa against various antibiotics. Pak J Pharm Sci 21 (2008) 311-315
41. Hoogkamp-Korstanje J.A., and Westerdaal N.A. In vitro susceptibility of pseudomonas to four beta-lactam antibiotics (ampicillin, cephalothin, carbenicillin, piperacillin), to four aminoglycosides (kanamycin, amikacin, gentamicin, tobramycin) and to colimycin. Chemotherapy 25 (1979) 48-53
42. Korvick J., Yu V.L., and Hilf M. Susceptibility of 100 blood isolates of Pseudomonas aeruginosa to 19 antipseudomonal antibiotics: old and new. Diagn Microbiol Infect Dis 7 (1987) 107-111
43. Cavallo J.D., Fabre R., Leblanc F., Nicolas-Chanoine M.H., and Thabaut A. Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study (1996). J Antimicrob Chemother 46 (2000) 133-136
44. Gales A.C., Jones R.N., Turnidge J., Rennie R., and Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 Suppl. 2 (2001) S146-S155
45. Tsuji M., Takema M., Miwa H., Shimada J., and Kuwahara S. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob Agents Chemother 47 (2003) 2507-2512
46. Takeda S., Nakai T., Wakai Y., Ikeda F., and Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51 (2007) 826-830
47. Khorasani G., Salehifar E., and Eslami G. Profile of microorganisms and antimicrobial resistance at a tertiary care referral burn centre in Iran: emergence of Citrobacter freundii as a common microorganism. Burns 34 (2008) 947-952
48. Strateva T., Ouzounova-Raykova V., Markova B., Todorova A., Marteva-Proevska Y., and Mitov I. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol 56 (2007) 956-963
49. Chaudhury A. In vitro activity of cefpirome: a new fourth generation cephalosporin. Indian J Med Microbiol 21 (2003) 52-55
50. Gonzalez III L.S., and Spencer J.P. Aminoglycosides: a practical review. Am Fam Physician 58 (1998) 1811-1820
51. Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 479-487
52. Cavallo J.D., Hocquet D., Plesiat P., Fabre R., and Roussel-Delvallez M. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J Antimicrob Chemother 59 (2007) 1021-1024
53. Miller G.H., Sabatelli F.J., Hare R.S., Glupczynski Y., Mackey P., Shlaes D., et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 24 Suppl. 1 (1997) S46-S62
54. Stone H.H. Review of pseudomonas sepsis in thermal burns: verdoglobin determination and gentamicin therapy. Ann Surg 163 (1966) 297-305
55. Acar J.F., and Goldstein F.W. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24 Suppl. 1 (1997) S67-S73
56. Messadi A.A., Lamia T., Kamel B., Salima O., Monia M., and Saida B.R. Association between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in an intensive care burn unit: a 5-year study, 2000-2004. Burns 34 (2008) 1098-1102
57. Fedler K.A., Biedenbach D.J., and Jones R.N. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 56 (2006) 427-436
58. Karlowsky J.A., Jones M.E., Thornsberry C., Evangelista A.T., Yee Y.C., and Sahm D.F. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 40 Suppl. 2 (2005) S89-S98
59. Gold H.S., and Moellering Jr. R.C. Antimicrobial-drug resistance. N Engl J Med 335 (1996) 1445-1453